Femto Biomed and MCurex Promote Development of mRNA-Based Immuno-Oncology Drugs

Femto Biomed CI

[Asia Economy Reporter Chunhee Lee] Femto Biomed announced on the 2nd that it has signed a Memorandum of Understanding (MOU) for research and development of mRNA-based NK cell therapy with MCurex, an mRNA specialist company and a subsidiary of Olix.

The two companies plan to develop an immuno-oncology drug that activates NK cells by injecting mRNA, applied with MCurex's technology, into NK cells through Femto Biomed's delivery technology. To this end, they will exchange technical information necessary for drug development and jointly establish commercialization strategies, advancing technical collaboration.

Femto Biomed is a bio company developing NK cell therapy platform technology. Using its proprietary CellShot technology, it is developing therapies that induce immune-oncology effects by directly delivering various cancer antigens and functional molecules into the cytoplasm or nucleus without mediators. At the end of last year, it also developed technology to successfully deliver mRNA into NK cells.

MCurex is a subsidiary established last year by Olix, a company specializing in RNA interference therapeutics, to develop mRNA vaccines and therapeutics. It has established an independent mRNA platform technology that does not infringe on patents used in existing COVID-19 vaccines and has completed the development of a COVID-19 mRNA vaccine candidate.

Hong Sunwoo, CEO of MCurex, said, “Through this collaboration, we expect to successfully develop next-generation immuno-oncology drugs that can accelerate the era of conquering cancer.” Lee Sanghyun, CEO of Femto Biomed, said, “The cooperation between the two companies will be the foundation for Korea’s bio industry to achieve self-reliance in future advanced cell therapy technologies.”

This content was produced with the assistance of AI translation services.